Feb 5, 2026 08:54AM RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity'

Feb 2, 2026 08:39AM Mizuho on EyePoint Inc. (EYPT): 'Competitor P3 Data Coming, So Expect Volatility; Recent Weakness Provides an Opportunity'

Jan 7, 2026 09:55AM Mizuho: 'we again highlight EYPT as a top pick for 2026'

Jan 7, 2026 09:02AM RBC Capital on EyePoint Inc. (EYPT): 'we see weighted avg. upside of ~60% into EYPT's wAMD Phase III readout'

Jan 7, 2026 07:03AM EyePoint advances retinal drug trials with 2026 data readouts expected

Jan 2, 2026 10:00PM Here are Mizuho's top Biotech pick for 2026

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Dec 9, 2025 10:49AM Mizuho on EyePoint Inc. (EYPT): 'Competitor Makes a Move for the Pole Position; Reiterate OP, as We're Not Concerned'

Dec 8, 2025 09:55AM EyePoint Pharmaceuticals (EYPT) Changes Names to Eyepoint Inc - SEC

Nov 20, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Nov 5, 2025 07:05AM EyePoint Pharmaceuticals (EYPT) Misses Q3 EPS by 8c

Oct 20, 2025 06:55AM Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 14, 2025 04:24PM EyePoint Pharmaceuticals (EYPT) files mixed shelf

Oct 2, 2025 06:38AM Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Aug 14, 2025 01:52PM EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $28 at Mizuho

Aug 6, 2025 07:03AM EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c

May 30, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

May 27, 2025 12:20PM JPMorgan on EyePoint Pharmaceuticals, Inc. (EYPT): 'We are pleased to see EyePoint’s continued execution'

May 16, 2025 05:35AM EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $26 at Mizuho

May 7, 2025 07:06AM EyePoint Pharmaceuticals (EYPT) Tops Q1 EPS by 2c

Mar 17, 2025 10:33AM Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Mar 17, 2025 10:00AM These 11 stocks are Mizuho's Aging Intelligence (AI) top picks

Mar 6, 2025 07:24AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Mar 5, 2025 07:04AM EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 14c

Feb 5, 2025 10:19AM TD Cowen Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Feb 5, 2025 08:23AM EyePoint Pharmaceuticals' (EYPT) decline "makes no sense", says Cantor Fitzgerald

Feb 5, 2025 07:01AM EyePoint Pharmaceuticals (EYPT) Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

Jan 13, 2025 07:07AM EyePoint Pharmaceuticals (EYPT) Provides Company Update and Anticipated Development Milestones for 2025

Jan 8, 2025 07:02AM EyePoint Pharmaceuticals (EYPT) Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

Jan 7, 2025 05:01AM Citi Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy

Dec 4, 2024 07:03AM EyePoint Pharmaceuticals (EYPT) Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Nov 11, 2024 08:40AM EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $33 at Baird

Nov 11, 2024 07:24AM EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright

Nov 7, 2024 05:14PM EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c

Oct 30, 2024 06:07AM EyePoint Pharmaceuticals (EYPT) Prices Upsized 12.73M Share Offering at $11/sh

Oct 28, 2024 05:14PM EyePoint Pharmaceuticals (EYPT) Announces Proposed $100M Share Offering

Oct 28, 2024 02:23PM Guggenheim Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 28, 2024 10:59AM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 28, 2024 07:00AM EyePoint Pharmaceuticals (EYPT) Reports Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU

Oct 25, 2024 08:06AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 25, 2024 05:52AM CapitalOne Reiterates Underweight Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 24, 2024 02:34PM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Oct 24, 2024 07:02AM EyePoint Pharmaceuticals (EYPT) Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Sep 4, 2024 07:01AM EyePoint Pharmaceuticals (EYPT) Appoints Fred Hassan to its Board

Aug 28, 2024 02:16AM Jefferies Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy

Aug 7, 2024 07:07AM EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c

Jun 27, 2024 12:30PM TD Cowen Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Jun 27, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Jun 26, 2024 03:45PM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

Jun 26, 2024 08:01AM EyePoint Pharmaceuticals (EYPT) to Highlight DURAVYUTM Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024